{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:00:45Z","timestamp":1780473645268,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41375-026-02919-0","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T07:53:05Z","timestamp":1774857185000},"page":"1203-1213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic significance of clinical risk models and genomic alterations in Waldenstr\u00f6m macroglobulinemia before or after the BTK inhibitor era"],"prefix":"10.1038","volume":"40","author":[{"given":"Yuting","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0448-7210","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8621-4840","authenticated-orcid":false,"given":"Mu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4922-4614","authenticated-orcid":false,"given":"Gang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8752-0644","authenticated-orcid":false,"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Chinese Workshop of Indolent Lymphomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2919_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/sonc.2003.50082","volume":"30","author":"RG Owen","year":"2003","unstructured":"Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstrom\u2019s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia. Semin Oncol. 2003;30:110\u20135.","journal-title":"Semin Oncol"},{"key":"2919_CR2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0001","volume":"22","author":"SK Kumar","year":"2024","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Baz R, et al. Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma, version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22. e240001.","journal-title":"J Natl Compr Canc Netw"},{"key":"2919_CR3","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/ajh.27666","volume":"100","author":"MA Gertz","year":"2025","unstructured":"Gertz MA. Waldenstr\u00f6m macroglobulinemia: 2025 update on diagnosis, risk stratification, and management. Am J Hematol. 2025;100:1061\u201373.","journal-title":"Am J Hematol"},{"key":"2919_CR4","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1182\/blood.2019000725","volume":"134","author":"MA Dimopoulos","year":"2019","unstructured":"Dimopoulos MA, Kastritis E. How I treat Waldenstr\u00f6m macroglobulinemia. Blood. 2019;134:2022\u201335.","journal-title":"Blood"},{"key":"2919_CR5","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1200710","volume":"367","author":"SP Treon","year":"2012","unstructured":"Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia. New Engl J Med. 2012;367:826\u201333.","journal-title":"New Engl J Med"},{"key":"2919_CR6","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","volume":"123","author":"ZR Hunter","year":"2014","unstructured":"Hunter ZR, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123:1637\u201346.","journal-title":"Blood"},{"key":"2919_CR7","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","volume":"123","author":"SP Treon","year":"2014","unstructured":"Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123:2791\u20136.","journal-title":"Blood"},{"key":"2919_CR8","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1158\/1078-0432.CCR-15-0646","volume":"22","author":"S Poulain","year":"2016","unstructured":"Poulain S, Roumier C, Venet-Caillault A, Figeac M, Herbaux C, Marot G, et al. Genomic landscape of CXCR4 mutations in Waldenstr\u00f6m macroglobulinemia. Clin Cancer Res. 2016;22:1480\u20138.","journal-title":"Clin Cancer Res"},{"key":"2919_CR9","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","volume":"122","author":"G Yang","year":"2013","unstructured":"Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m macroglobulinemia. Blood. 2013;122:1222\u201332.","journal-title":"Blood"},{"key":"2919_CR10","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1182\/blood-2016-01-695098","volume":"127","author":"G Yang","year":"2016","unstructured":"Yang G, Buhrlage SJ, Tan L, Liu X, Chen J, Xu L, et al. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016;127:3237\u201352.","journal-title":"Blood"},{"key":"2919_CR11","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1182\/bloodadvances.2021006106","volume":"6","author":"JJ Castillo","year":"2022","unstructured":"Castillo JJ, Sarosiek SR, Gustine JN, Flynn CA, Leventoff CR, White TP, et al. Response and survival predictors in a cohort of 319 patients with Waldenstr\u00f6m macroglobulinemia treated with ibrutinib monotherapy. Blood Adv. 2022;6:1015\u201324.","journal-title":"Blood Adv"},{"key":"2919_CR12","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1200\/JCO.19.02314","volume":"38","author":"SP Treon","year":"2020","unstructured":"Treon SP, Xu L, Guerrera ML, Jimenez C, Hunter ZR, Liu X, et al. Genomic landscape of Waldenstr\u00f6m macroglobulinemia and its impact on treatment strategies. J Clin Oncol. 2020;38:1198\u2013208.","journal-title":"J Clin Oncol"},{"key":"2919_CR13","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","volume":"113","author":"P Morel","year":"2009","unstructured":"Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113:4163\u201370.","journal-title":"Blood"},{"key":"2919_CR14","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1038\/s41375-019-0431-y","volume":"33","author":"E Kastritis","year":"2019","unstructured":"Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsonis MC, Durot E, et al. A revised international prognostic score system for Waldenstr\u00f6m\u2019s macroglobulinemia. Leukemia. 2019;33:2654\u201361.","journal-title":"Leukemia"},{"key":"2919_CR15","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.23.02066","volume":"42","author":"S Zanwar","year":"2024","unstructured":"Zanwar S, Le-Rademacher J, Durot E, D\u2019Sa S, Abeykoon JP, Mondello P, et al. Simplified risk stratification model for patients with Waldenstr\u00f6m macroglobulinemia. J Clin Oncol. 2024;42:2527\u201336.","journal-title":"J Clin Oncol"},{"key":"2919_CR16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/bjh.15049","volume":"180","author":"SP Treon","year":"2018","unstructured":"Treon SP, Gustine J, Xu L, Manning RJ, Tsakmaklis N, Demos M, et al. MYD88 wild-type Waldenstrom macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018;180:374\u201380.","journal-title":"Br J Haematol"},{"key":"2919_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/ajh.24955","volume":"93","author":"JP Abeykoon","year":"2018","unstructured":"Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR, et al. MYD88 mutation status does not impact overall survival in Waldenstr\u00f6m macroglobulinemia. Am J Hematol. 2018;93:187\u201394.","journal-title":"Am J Hematol"},{"key":"2919_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.neo.2021.02.002","volume":"23","author":"Y Wang","year":"2021","unstructured":"Wang Y, Gali VL, Xu-Monette ZY, Sano D, Thomas SK, Weber DM, et al. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr\u00f6m macroglobulinemia. Neoplasia. 2021;23:361\u201374.","journal-title":"Neoplasia"},{"key":"2919_CR19","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/ajh.26339","volume":"96","author":"D Krzisch","year":"2021","unstructured":"Krzisch D, Guedes N, Boccon-Gibod C, Baron M, Bravetti C, Davi F, et al. Cytogenetic and molecular abnormalities in Waldenstr\u00f6m\u2019s macroglobulinemia patients: correlations and prognostic impact. Am J Hematol. 2021;96:1569\u201379.","journal-title":"Am J Hematol"},{"key":"2919_CR20","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1158\/1078-0432.CCR-23-3939","volume":"30","author":"Y Yan","year":"2024","unstructured":"Yan Y, Yu Y, Xiong W, Wang J, Yao Y, Jia Y, et al. Determination of MYD88 and CXCR4 mutations for clinical detection and their significance in Waldenstr\u00f6m macroglobulinemia. Clin Cancer Res. 2024;30:5483\u201393.","journal-title":"Clin Cancer Res"},{"key":"2919_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00916-5","volume":"13","author":"WL Chan","year":"2023","unstructured":"Chan WL, Chong VCL, Wee IJY, Poon LM, Chan EHL, Lee J, et al. Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis. Blood cancer J. 2023;13:140.","journal-title":"Blood cancer J"},{"key":"2919_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00277-022-05019-y","volume":"102","author":"Z Liu","year":"2023","unstructured":"Liu Z, Jiang S, Gu J, Liu H, Song G, Cao X. Bortezomib-based chemotherapy for patients with Waldenstr\u00f6m macroglobulinemia: a single-center experience. Ann Hematol. 2023;102:167\u201374.","journal-title":"Ann Hematol"},{"key":"2919_CR23","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","volume":"27","author":"SP Treon","year":"2009","unstructured":"Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, et al. Primary therapy of Waldenstr\u00f6m macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27:3830\u20135.","journal-title":"J Clin Oncol"},{"key":"2919_CR24","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1200\/JCO.22.01805","volume":"41","author":"C Buske","year":"2023","unstructured":"Buske C, Dimopoulos MA, Grunenberg A, Kastritis E, Tomowiak C, Mah\u00e9 B, et al. Bortezomib-dexamethasone, rituximab, and cyclophosphamide as first-line treatment for Waldenstr\u00f6m\u2019s macroglobulinemia: a prospectively randomized trial of the European Consortium for Waldenstr\u00f6m\u2019s macroglobulinemia. J Clin Oncol. 2023;41:2607\u201316.","journal-title":"J Clin Oncol"},{"key":"2919_CR25","first-page":"1614","volume":"109","author":"W Xiong","year":"2024","unstructured":"Xiong W, Lyu R, Yu Y, Wang T, Yan Y, Wang Y, et al. Rituximab plus cyclophosphamide and dexamethasone versus bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenstr\u00f6m macroglobulinemia: a randomized controlled trial. Haematologica. 2024;109:1614\u20138.","journal-title":"Haematologica"},{"key":"2919_CR26","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMc1506192","volume":"373","author":"SP Treon","year":"2015","unstructured":"Treon SP, Xu L, Hunter Z. MYD88 mutations and response to ibrutinib in Waldenstr\u00f6m\u2019s macroglobulinemia. New Engl J Med. 2015;373:584\u20136.","journal-title":"New Engl J Med"},{"key":"2919_CR27","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.1182\/bloodadvances.2020003010","volume":"4","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Sanz RG, Lee HP, Trneny M, Varettoni M, Opat S, et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenstr\u00f6m macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv. 2020;4:6009\u201318.","journal-title":"Blood Adv"},{"key":"2919_CR28","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/bjh.16088","volume":"187","author":"JJ Castillo","year":"2019","unstructured":"Castillo JJ, Xu L, Gustine JN, Keezer A, Meid K, Dubeau TE, et al. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstr\u00f6m macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019;187:356\u201363.","journal-title":"Br J Haematol"},{"key":"2919_CR29","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjh.15560","volume":"184","author":"JN Gustine","year":"2019","unstructured":"Gustine JN, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, et al. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstr\u00f6m macroglobulinaemia. Br J Haematol. 2019;184:242\u20135.","journal-title":"Br J Haematol"},{"key":"2919_CR30","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1182\/bloodadvances.2023010906","volume":"8","author":"CS Tam","year":"2024","unstructured":"Tam CS, Opat S, D\u2019Sa S, Jurczak W, Lee HP, Cull G, et al. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstr\u00f6m macroglobulinemia. Blood Adv. 2024;8:1639\u201350.","journal-title":"Blood Adv"},{"key":"2919_CR31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3324\/haematol.2012.070458","volume":"98","author":"F Nguyen-Khac","year":"2013","unstructured":"Nguyen-Khac F, Lambert J, Chapiro E, Grelier A, Mould S, Barin C, et al. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstr\u00f6m\u2019s macroglobulinemia. Haematologica. 2013;98:649\u201354.","journal-title":"Haematologica"},{"key":"2919_CR32","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"2919_CR33","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1158\/1078-0432.CCR-12-0845","volume":"18","author":"A Gonzalez-Aguilar","year":"2012","unstructured":"Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res. 2012;18:5203\u201311.","journal-title":"Clin Cancer Res"},{"key":"2919_CR34","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1182\/blood.2019001880","volume":"134","author":"RI Panea","year":"2019","unstructured":"Panea RI, Love CL, Shingleton JR, Reddy A, Bailey JA, Moormann AM, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019;134:1598\u2013607.","journal-title":"Blood"},{"key":"2919_CR35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cell.2020.05.049","volume":"182","author":"L Venturutti","year":"2020","unstructured":"Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D, et al. TBL1XR1 mutations drive extranodal lymphoma by inducing a pro-tumorigenic memory fate. Cell. 2020;182:297\u2013316.e27.","journal-title":"Cell"},{"key":"2919_CR36","volume":"21","author":"H Hosoi","year":"2024","unstructured":"Hosoi H, Tabata S, Kosako H, Hori Y, Okamura T, Yamashita Y, et al. IGLL5, controlled by a super-enhancer, affects cell survival and MYC expression in mature B-cell lymphoma. Leuk Res Rep. 2024;21:100451.","journal-title":"Leuk Res Rep"},{"key":"2919_CR37","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.3324\/haematol.2017.172718","volume":"102","author":"M Varettoni","year":"2017","unstructured":"Varettoni M, Zibellini S, Defrancesco I, Ferretti VV, Rizzo E, Malcovati L, et al. Pattern of somatic mutations in patients with Waldenstr\u00f6m macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica. 2017;102:2077\u201385.","journal-title":"Haematologica"},{"key":"2919_CR38","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO.2016.71.0814","volume":"35","author":"ZR Hunter","year":"2017","unstructured":"Hunter ZR, Yang G, Xu L, Liu X, Castillo JJ, Treon SP. Genomics, signaling, and treatment of waldenstr\u00f6m macroglobulinemia. J Clin Oncol. 2017;35:994\u20131001.","journal-title":"J Clin Oncol"},{"key":"2919_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115\u20139.","journal-title":"Nature"},{"key":"2919_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00351-w","volume":"10","author":"W Shuai","year":"2020","unstructured":"Shuai W, Lin P, Strati P, Patel KP, Routbort MJ, Hu S, et al. Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. Blood Cancer J. 2020;10:86.","journal-title":"Blood Cancer J"},{"key":"2919_CR41","doi-asserted-by":"publisher","first-page":"e0167641","DOI":"10.1371\/journal.pone.0167641","volume":"11","author":"JA Kim","year":"2016","unstructured":"Kim JA, Hwang B, Park SN, Huh S, Im K, Choi S, et al. Genomic profile of chronic lymphocytic leukemia in Korea identified by targeted sequencing. PloS one. 2016;11:e0167641.","journal-title":"PloS one"},{"key":"2919_CR42","doi-asserted-by":"publisher","DOI":"10.1177\/20406207251321721","volume":"16","author":"H Fu","year":"2025","unstructured":"Fu H, Wang T, Yang Y, Qiu C, Wang H, Qiu Y, et al. Next-generation sequencing of circulating tumor DNA in cerebrospinal fluid for detecting gene mutations in central nervous system lymphoma patients. Ther Adv Hematol. 2025;16:20406207251321721.","journal-title":"Ther Adv Hematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02919-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02919-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02919-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:03:38Z","timestamp":1780470218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02919-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2919"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02919-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}